Anti-PD-1/PD-L1 antibodies are emerging as promising anticancer therapeutics. Interestingly, elevated response rates to these agents are mostly documented among patients with tumors that bear high level of somatic mutations, like melanoma or non-small cell lung carcinoma. We herein formulate the hypothesis that high levels of mutational heterogeneity in the tumor could be the key for the success of immune checkpoint-targeting therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937193 | PMC |
| http://dx.doi.org/10.4161/onci.27817 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy.
Oncoimmunology
January 2014
Drug Development Department (DITEP); Gustave Roussy; University Paris Sud; Villejuif, France ; INSERM U981; Gustave Roussy; University Paris Sud; Villejuif, France ; SIRIC SOCRATE; Gustave Roussy; University Paris Sud; Villejuif, France ; Thoracic Multidisciplinary Committee; Gustave Roussy; University Paris Sud; Villejuif, France.
Anti-PD-1/PD-L1 antibodies are emerging as promising anticancer therapeutics. Interestingly, elevated response rates to these agents are mostly documented among patients with tumors that bear high level of somatic mutations, like melanoma or non-small cell lung carcinoma. We herein formulate the hypothesis that high levels of mutational heterogeneity in the tumor could be the key for the success of immune checkpoint-targeting therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!